Emergent Biosolutions (NYSE:EBS) Posts Earnings Results, Beats Expectations By $0.68 EPS

Emergent Biosolutions (NYSE:EBS) posted its earnings results on Wednesday. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.68, FiscalAI reports. The business had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a positive return on equity of 14.83% and a negative net margin of 22.95%.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Q2 results exceeded expectations, with revenue of $234 million and adjusted EBITDA of $97 million, up from $33 million a year earlier. Medical countermeasure deliveries to U.S. government customers were accelerated, driving much of the outperformance.
• The medical countermeasures business remains a key growth driver, with Q2 revenue of $168 million and new contract modifications totaling $117.2 million for ACAM2000 and botulism antitoxin. International MCM sales represented about 20% of first-half MCM revenue.
• Emergent lowered 2026 revenue guidance to $645 million-$675 million from $720 million-$760 million and reduced adjusted EBITDA guidance to $130 million-$150 million, citing increased competition, pricing pressure, and volume pressure in the naloxone market.
• The company recorded a $191 million non-cash impairment charge against its NARCAN asset group and expects further price erosion as new nasal naloxone competitors enter the market. Emergent said total naloxone unit demand may remain roughly flat while it works to defend its more-than-50% market share.
• Emergent is restructuring to generate approximately $40 million in annualized savings, including about 90 job reductions, facility closures, and other footprint changes; most savings are expected to be realized in 2027. Liquidity also improved through accounts-receivable collections, debt refinancing, and lower gross debt.

Emergent Biosolutions Stock Performance

Shares of Emergent Biosolutions stock traded down $0.30 during trading hours on Friday, hitting $5.00. 1,745,199 shares of the company were exchanged, compared to its average volume of 876,122. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. The business has a 50-day moving average of $7.90 and a 200-day moving average of $8.79. Emergent Biosolutions has a 1 year low of $4.98 and a 1 year high of $14.06. The stock has a market capitalization of $258.24 million, a price-to-earnings ratio of -1.41 and a beta of 2.35.

Insiders Place Their Bets

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the transaction, the senior vice president directly owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by company insiders.

Institutional Trading of Emergent Biosolutions

Several hedge funds and other institutional investors have recently made changes to their positions in EBS. Legal & General Group Plc acquired a new position in shares of Emergent Biosolutions during the second quarter worth about $31,000. CANADA LIFE ASSURANCE Co purchased a new stake in Emergent Biosolutions in the 4th quarter valued at approximately $45,000. Raymond James Financial Inc. purchased a new stake in Emergent Biosolutions in the 2nd quarter valued at approximately $53,000. BNP Paribas Financial Markets increased its position in Emergent Biosolutions by 133.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,942 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 6,246 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new position in Emergent Biosolutions during the 4th quarter worth approximately $107,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on EBS shares. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings downgraded Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Finally, UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $12.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.